carbamates has been researched along with Acquired Immune Deficiency Syndrome in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amprenavir is an HIV-1 protease inhibitor which is hepatically metabolized (>80%) with a low renal elimination." | 5.34 | [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency]. ( Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I, 2007) |
| "Amprenavir is an HIV-1 protease inhibitor which is hepatically metabolized (>80%) with a low renal elimination." | 1.34 | [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency]. ( Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I, 2007) |
| "Fosamprenavir 700 mg bid was then added to the regimen, and pharmacokinetic sampling was repeated for all 3 agents at day 11." | 1.32 | Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. ( Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A, 2004) |
| " Progress is also highlighted about dosing regimens, antiretroviral resistance, and reconstitution of the immune system." | 1.30 | Moving forward: a treatment overview from the 12th World AIDS Conference. ( Agosto, M, 1998) |
| " Each drug trial demonstrates the relationship between dosing and resistance; patients are advised to adhere completely to dosing instructions." | 1.29 | Protease inhibitors and prevention of cross resistance. ( Levin, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Balagopal, A | 1 |
| Smeaton, LM | 1 |
| Quinn, J | 1 |
| Venuto, CS | 1 |
| Morse, GD | 1 |
| Vu, V | 1 |
| Alston-Smith, B | 1 |
| Cohen, DE | 1 |
| Santana-Bagur, JL | 1 |
| Anthony, DD | 1 |
| Sulkowski, MS | 1 |
| Wyles, DL | 1 |
| Talal, AH | 1 |
| Abbasi, NR | 1 |
| Wang, N | 1 |
| ROBISON, JM | 1 |
| Gallant, JE | 1 |
| Bates, SM | 1 |
| Page, KB | 1 |
| Nakielny, RA | 1 |
| Talbot, MD | 1 |
| Basso, S | 1 |
| Solas, C | 1 |
| Quinson, AM | 1 |
| Ravaux, I | 1 |
| Poizot-Martin, I | 1 |
| Bacconier, J | 1 |
| Durand, A | 1 |
| Lacarelle, B | 1 |
| Boffito, M | 1 |
| Dickinson, L | 1 |
| Hill, A | 1 |
| Back, D | 1 |
| Moyle, G | 1 |
| Nelson, M | 1 |
| Higgs, C | 1 |
| Fletcher, C | 1 |
| Gazzard, B | 1 |
| Pozniak, A | 1 |
| Janus, N | 1 |
| Launay-Vacher, V | 1 |
| Izzedine, H | 1 |
| Karie, S | 1 |
| Laville, I | 1 |
| Deray, G | 1 |
| Livington, DJ | 1 |
| Pazhanisamy, S | 1 |
| Porter, DJ | 1 |
| Partaledis, JA | 1 |
| Tung, RD | 1 |
| Painter, GR | 1 |
| Gracia Jones, S | 1 |
| Baggett, TH | 1 |
| Roca, B | 1 |
| Tomás, G | 1 |
| Climent, A | 1 |
| Tomasselli, AG | 1 |
| Heinrikson, RL | 1 |
| Koch, CA | 1 |
| Wolkersdoerfer, G | 1 |
| Kost, RG | 1 |
| Hurley, A | 1 |
| Zhang, L | 1 |
| Vesanen, M | 1 |
| Talal, A | 1 |
| Furlan, S | 1 |
| Caldwell, P | 1 |
| Johnson, J | 1 |
| Smiley, L | 1 |
| Ho, D | 1 |
| Markowitz, M | 1 |
| Levin, J | 1 |
| Agosto, M | 1 |
| Bart, PA | 1 |
| Rizzardi, PG | 1 |
| Gallant, S | 1 |
| Golay, KP | 1 |
| Baumann, P | 1 |
| Pantaleo, G | 1 |
| Eap, CB | 1 |
| Gallant, DM | 1 |
| Head-Dunham, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz[NCT00001758] | Phase 2 | 25 participants | Interventional | 1997-11-30 | Completed | ||
| Pharmacokinetic Interactions Between Ritonavir, Amprenavir and Efavirenz and Nelfinavir, Amprenavir, and Efavirenz in People Infected With HIV[NCT00001766] | Phase 1 | 22 participants | Interventional | 1998-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carbamates and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Clinical update: new drugs for HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Che | 1999 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as T | 2000 |
3 trials available for carbamates and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; | 2020 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 L | 2001 |
Protease inhibitor trial started.
Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Furans; HIV Protease Inhibitors; Humans; Indi | 1998 |
18 other studies available for carbamates and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; | 2013 |
Doxorubicin-induced hyperpigmentation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Th | 2008 |
A pressure splint which aids in closing an oral antralalveolar fistula.
Topics: Acquired Immunodeficiency Syndrome; Carbamates; Fistula; Humans; Oral Fistula; Organometallic Compou | 1947 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2001 |
Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Cushing Syndrome; Diagnosis, | 2002 |
Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; F | 2002 |
[Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; Clinical Trials as Topic; Dose-Response Relationship | 2003 |
[No selection of mutations. 908 raises genetic resistance barrier].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; DNA Mutational Analysis; Drug Resistance, Multiple, | 2003 |
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration S | 2004 |
[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Kidn | 2007 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Stevens-Johnson syndrome after exposure to a pesticide in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Dichlorvos; Humans; Male; Pesticides; Stevens | 1999 |
[Hyperlipoproteineumia in HIV patients undergoing antiretroviral therapy: which risk is greater--pancreatitis or coronary disease?].
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Anti-HIV Agents; Carbamates; Coronary Disease; Di | 2000 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, C | 1998 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Micro | 1995 |
Moving forward: a treatment overview from the 12th World AIDS Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; | 1998 |
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Carbamates; Dideoxynucleosides; Drug Interac | 2001 |
Antabuse (disulfiram) and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alcoholism; Aldehyde Dehydrogenase; Carbamates; CD4-Positive T-L | 1991 |